Lataa...
Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations
Ibrutinib is the first covalent inhibitor of Bruton's tyrosine kinase (BTK) to be used in the treatment of B-cell cancers. Understanding the mechanism of covalent inhibition will aid in the design of safer and more selective covalent inhibitors that target BTK. The mechanism of covalent inhibit...
Tallennettuna:
| Julkaisussa: | Chem Sci |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
The Royal Society of Chemistry
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8097726/ https://ncbi.nlm.nih.gov/pubmed/33995994 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/d0sc06122k |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|